Regulatory milestones

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) gained $1.91 (11%) to $19.40 Independence Day week after the European Commission approved Iclusig ponatinib to treat chronic myelogenous leukemia (CML) and Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).